Figure 3
![OS and PFS in 26 patients with good risk features. Patients allografted since 2001 with chemosensitive disease and good performance status at the time of allogeneic HSCT show a favorable outcome (overall survival [OS], solid line; progression-free survival [PFS], dotted line).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/114/10/10.1182_blood-2008-11-189399/4/zh89990939950003.jpeg?Expires=1720851241&Signature=2BUby80wE8DFu0E8H~U9TMWrDQRw9TgmIVsgOkihct22~KUULA-kXCdlHNo1SkqQBf8e7j-F9vMjyiwkTpAlWWsFZ-4Iole~1-6P89ZOoAFehk5YP9nUaDTeq7H2YxosoQ2fyrkuWSdo7KaG2q31UiEV2-LLoN3YJKcmDwEqoqaeWgCb9tH4bjYZQnL2lU-N64rRHtKbGGT19qW~03rxQ-IA43OS1vAZFUYMjJDHXkppxQET0CnReGUmIjRW4wdyxsyGXRMIZx-JXt8Vh239xBg~~emlN3rGqzqxeB3bYjIvgNT~-G60f7RNxXHEYWymVp16qpUD~AuKmQOZ28IIrA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
OS and PFS in 26 patients with good risk features. Patients allografted since 2001 with chemosensitive disease and good performance status at the time of allogeneic HSCT show a favorable outcome (overall survival [OS], solid line; progression-free survival [PFS], dotted line).
